Prognostic significance of PRAME expression based on immunohistochemistry for diffuse large B-cell lymphoma patients treated with R-CHOP therapy by Mitsuhashi Kenjiro et al.
Prognostic significance of PRAME expression
based on immunohistochemistry for diffuse
large B-cell lymphoma patients treated with
R-CHOP therapy
journal or
publication title
International Journal of Hematology
volume 100
number 1
page range 88-95
year 2014-07
URL http://hdl.handle.net/10470/31358
 
 
1 
Prognostic significance of PRAME expression based on immunohistochemistry for diffuse large B-cell 
lymphoma patients treated with R-CHOP therapy 
Kenjiro Mitsuhashi1, Akihiro Masuda2, Yan-Hua Wang1, Masayuki Shiseki1, Toshiko Motoji1 
 
1Department of Hematology, Tokyo Women’s Medical University 
2Department of Surgical Pathology, Tokyo Women’s Medical University  
 
Running head: PRAME expression based on IHC in DLBCL 
Manuscript type: Original article 
 
Corresponding author: 
Kenjiro Mitsuhashi 
Address: 8-1, Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan 
Phone: +81-3-3353-8111 
Fax: +81-3-5269-7329 
E-mail: mitsuhashi@dh.twmu.ac.jp  
 
 
 
2 
Abstract 
The preferentially expressed antigen of melanoma (PRAME), a tumor-associated antigen, is considered 
a prognostic marker for various human malignancies. The prognostic significance of PRAME expression 
for diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab-containing chemotherapy has 
not been evaluated to date, and the ability of immunohistochemistry (IHC) to detect PRAME expression 
in these patients has not yet been studied, although IHC is simple to perform in clinical practice. We 
evaluated the prognostic significance of PRAME expression based on IHC analysis in 160 DLBCL 
patients treated with R-CHOP therapy. There was a significant association between higher PRAME 
expression and shorter progression-free survival (PFS), and a trend toward shorter overall survival (OS) 
in patients with higher PRAME expression than that in patients with lower PRAME expression (5 year-
PFS, 48.1% vs 61.1%; 5 year-OS, 65.6% vs 79.1%). Patients with high PRAME expression tended to 
have lower chemotherapeutic responses. Thus, IHC is useful for detecting and assessing PRAME 
expression in DLBCL. Further, we found a positive correlation between IHC and quantitative real-time 
RT-PCR measurements of PRAME expression. Our findings indicate that IHC results of PRAME 
expression can be a novel prognostic maker in DLBCL patients treated with R-CHOP therapy. 
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1. Introduction 
The preferentially expressed antigen of melanoma (PRAME) was initially isolated as a human 
melanoma antigen that is recognized by cytotoxic T cells (CTL) [1,2]. Most normal tissues do not express 
PRAME, and only a weak expression of PRAME has been observed in the testis, ovaries, adrenal glands, 
and endometrial cells. In contrast, PRAME is over-expressed in a wide variety of human malignancies 
such as carcinoma [3], sarcoma [4,5], and hematologic malignancies [6-8]. Some studies have shown that 
in various types of solid tumors, PRAME expression is correlated with poor clinical outcome and 
advanced stage disease [3-5]. It has been reported that in acute and chronic leukemia, PRAME expression 
increases with disease progression [9-11]. On the other hand, high PRAME expression in childhood acute 
leukemia was shown to be a marker for a favorable prognosis [12,13]. Therefore, the clinical significance 
of PRAME expression is controversial in hematologic malignancies.  
Currently, the physiological function of PRAME is not completely understood. Thus far, it has been 
reported that PRAME acts as a dominant repressor of retinoic acid (RA) receptor signaling and that 
PRAME inhibits RA-induced cell differentiation and apoptosis [14]. Studies have also shown that the 
knockdown of PRAME in tumor cell lines can cause a decrease in cell proliferation and increase in 
apoptosis and cytotoxic drug sensitivity [4,9,15]. 
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma 
amongst adults, accounting for 30–40% of non-Hodgkin lymphoma cases. DLBCL is regarded as a 
heterogeneous disease that presents with a diversity of clinical features and biological characteristics [16]. 
A number of prognostic markers have been identified in DLBCL patients, including BCL2, BCL6, and 
cell of origin [17-19]. The introduction of rituximab as part of the chemotherapeutic regimen for patients 
with lymphoma has markedly improved the prognosis of DLBCL patients [20,21], and it invalidated 
prognostic markers that were previously considered to have a significant value [22-24]. Kawano et al. 
employed reverse transcriptase-polymerase chain reaction (RT-PCR) to examine the prognostic 
significance of PRAME expression in DLBCL patients, and they found that PRAME expression 
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correlated with shorter progression free survival (PFS) and lower chemotherapeutic responses in DLBCL 
patients treated with anthracycline-containing chemotherapy [25]. Thus far, the prognostic significance of 
PRAME expression has not been evaluated in DLBCL patients treated with rituximab-containing 
chemotherapy. Although it is easy to analyze protein expression in clinical practice using 
immunohistochemistry (IHC), this method has not been validated for the detection of PRAME expression 
in DLBCL. 
The aim of the present study was to determine the prognostic significance of PRAME expression based 
on IHC in DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and 
prednisolone (R-CHOP) therapy. In addition, we compared PRAME expression as measured by IHC and 
quantitative real-time RT-PCR (qRT-PCR). 
 
2. Materials and methods 
2.1 Patients and tissue samples 
We enrolled 160 patients with DLBCL, who were treated with R-CHOP therapy, at the Tokyo Women’s 
Medical University Hospital in Japan between December 2001 and February 2012. All patients were 
diagnosed according to the World Health Organization (WHO) criteria. We excluded patients with 
primary mediastinal large B-cell lymphoma, primary central nervous system lymphoma, and those with 
DLBCL that transformed from low-grade B-cell lymphoma. We analyzed the following clinical 
characteristics as recorded at the time of diagnosis: age, gender, performance status (PS), lactate 
dehydrogenase (LDH) levels, number of extranodal sites, disease stage (according to the Ann Arbor 
system [26]), the International Prognostic Index (IPI) [27], B symptoms, and bulky disease (more than 
10 cm). All patients (n = 160) received R-CHOP therapy. Twenty-six patients received involved-field 
radiotherapy following R-CHOP therapy. Autologous peripheral blood stem cell transplantation (auto-
PBSCT) was performed in 13 patients after R-CHOP therapy (1 patient received both radiotherapy and 
auto-PBSCT). 
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Tissue specimens were obtained at the initial presentation of patients, fixed in formalin, and embedded 
in paraffin. Cryopreserved tissue samples obtained at the same time were available in 40 patients. 
The study was approved by the Ethics Committee of Tokyo Women’s Medical University (approval 
number: 2550) and conducted in accordance with the Declaration of Helsinki. 
 
2.2 Immunohistochemistry 
 We immunohistochemically stained 4-μm sections of the formalin-fixed, paraffin-embedded tissue 
samples. The sections were deparaffinized in xylene and rehydrated in graded alcohol. Antigen retrieval 
was done with Target Retrieval Solution (pH 9; Dako, Glostrup, Denmark) and Pascal Pressurized 
Heating Chamber (Dako) treatment (125ºC, 40 minutes). We inhibited endogenous peroxidase activity by 
incubating the sections in 3% hydrogen peroxide for 5 minutes. The inhibition of endogenous peroxidase 
activity before MYC antibody was omitted in order to retain stable immunostainability. The sections were 
incubated at room temperature for 60 minutes with the following primary antibodies: anti-PRAME 
(1:400, polyclonal, Atlas, Stockholm, Sweden), CD5 (1:50, monoclonal, Dako), CD10 (1:100, 
monoclonal, Dako), BCL6 (1:10, monoclonal, Dako), MUM-1 (1:400, monoclonal, Abcam, Cambridge, 
United Kingdom), BCL2 (1:50, monoclonal, Dako), and MYC (1:600, monoclonal, Abcam). After 
incubation with primary antibodies, the sections were washed with phosphate buffered saline and then 
incubated with dextran coupled with peroxidase molecules and goat secondary antibody molecules 
against rabbit and mouse immunoglobulins (EnVision, Dako) for 20 minutes at room temperature. The 
color was developed with diaminobenzidine tetrahydrochloride chromogen, and the sections were 
counterstained with hematoxylin. We used 2 score categories (negative or positive) for CD5 expression, 
as described in the validation study by Salles et al. [28]. Based on the expression of CD10, BCL6, 
MUM-1, patients were classified as having the germinal center (GC) subtype or non-GC subtype, as 
defined by the Hans algorithm [29]. A double-hit score (DHS), previously described by Green et al. [30] 
and based on immunohistochemical MYC and BCL2 expression, was assigned. All sections were 
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evaluated independently by 2 hematopathologists who were blinded to the clinical outcomes of the 
patients. 
 
2.3 Quantitative real-time reverse transcriptase-polymerase chain reaction 
In total, 40 cryopreserved tissue samples from DLBCL patients were analyzed. Total RNA was extracted 
with TRIzol (Invitrogen, Carlsbad, CA, USA). One microgram of total RNA was converted to single-
stranded cDNA using a random primer and a High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA, USA) according to the manufacturer's protocols. We based our 
measurement of mRNA levels of PRAME on the TaqMan probe method, which utilizes an ABI 7500 real-
time system (Applied Biosystems) with co-amplification of the endogenous control gene human β-actin 
(Applied Biosystems). The real-time amplification reaction was performed in a total volume of 25 μL 
with a concentration of 300 nM for primers and 200 nM for probes. After adding 2.5 μL of cDNA and 
12.5 μL of TaqMan Gene Expression PCR Master Mix (Applied Biosystems), samples were amplified in 
duplicate wells for each experiment. The relative expression of PRAME was determined by the 
comparative CT method after normalization with β-actin gene. The human PRAME primer-probe sets 
were from Applied Biosystems (assay ID: Hs00196132_m1). 
 
2.4 Statistical analysis 
We considered the following factors to affect the prognosis of DLBCL patients: gender, age, PS, LDH, 
extranodal sites, disease stage, IPI score, B symptoms, bulky disease, cell of origin, CD5 expression, 
DHS, and PRAME expression as assessed by IHC. PFS was defined as the interval between the date of 
initial diagnosis and the date of disease progression or death as a result of any cause [31]. Overall survival 
(OS) was defined as the interval between the date of initial diagnosis and the date of death as a result of 
any cause, or the date of last follow-up. Chemotherapy response was assessed after R-CHOP therapy and 
classified as complete response (CR), partial response (PR), stable disease (SD), and progressive disease 
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(PD) according to the international workshop criteria [31]. PFS and OS were estimated by means of the 
Kaplan-Meier method, and a univariate analysis was performed by log-rank test. The hazard ratio was 
calculated by the Cox proportional hazard model. The association between PRAME expression by IHC 
and patient characteristics and chemotherapeutic response were compared with Chi-square analysis and 
Mann-Whitney test (age). A t-test was used to assess the correlation of PRAME expression between the 
IHC and qRT-PCR data. After adopting all factors (gender, age, PS, LDH, number of extranodal sites, 
stage, IPI score, B symptom, bulky disease, cell of origin, CD5 expression, DHS, and PRAME 
expression) that were used in the univariate analysis, the Cox proportional hazard model was performed 
as a multivariate analysis. Values of P < 0.05 were considered statistically significant. All statistical 
analyses were performed using JMP 11 (SAS Institute Japan Ltd.) software. 
 
3. Results 
3.1 Patient characteristics 
The characteristics of patients are summarized in Table I. The study cohort enrolled 74 female patients 
(46.2%) and 86 male patients (53.8%). The median age of patients was 66 years (range, 17–87 years), and 
105 patients (65.6%) were older than 60 years of age. Eighty-five patients (53.1%) had advanced disease 
(stage III or IV), 26 (16.3%) had a poor performance status (2–4), 108 (67.5%) had elevated LDH levels, 
67 (41.9%) had a high-intermediate or high risk (scores of 3, 4, or 5) as defined by IPI, 33 (20.6%) had B 
symptoms, and bulky disease was noted in 14 (8.8%) patients. Only 6 patients (3.8%) had positive CD5 
expression, whilst 106 patients (66.3%) were classified as having the non-GC subtype. The median 
follow-up was 2.7 years (range, 0.1–10.3 years). 
 
3.2 Analysis of PRAME expression by IHC 
The staining patterns of PRAME expression in tumor cells of DLBCL showed distinct cytoplasmic 
granules. Stainability varied between tumor cells (Fig. 1). Tumor cells were considered PRAME positive 
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even if they contained only small amounts of stained cytoplasmic granules. As stainability of 
immunohistochemical PRAME expression in DLBCL is not yet known, we classified all our patients into 
4 categories (0, 1+, 2+, and 3+) based on the percentage of PRAME positive tumor cells that they had 
(less than 25% were classified as 0; 25% or more but less than 50%, as 1+; 50% or more but less than 
75%, as 2+; and 75% or more, as 3+). We did not have any knowledge of patients’ clinical outcome. In 
total, 109 of the 160 patients (68.1%) were classified as 0; 17 (10.7%), as 1+; 13 (8.1%), as 2+; and 21 
(13.1%), as 3+.  
The optimal cutoff for PRAME expression by IHC was identified as the value equal to the maximum 
log-rank statistic that predicts patient survival. Univariate analysis showed that PRAME expression in our 
group of patients was associated with poor clinical outcome only when a cutoff point of 75% for positive 
tumor cell was selected. Therefore, we considered patients classified as 3+ (75% or more positive tumor 
cells) to have high PRAME expression (n = 21), and patients classified as 2+ or less (less than 75% 
positive tumor cells) to have low PRAME expression (n = 139) (Table I).  
Kaplan Meier estimates showed that patients with high PRAME expression had shorter PFS and OS 
than patients with low PRAME expression (Fig. 2). Furthermore, there was a significant association 
between a shorter PFS (P = 0.013) and a higher PRAME expression, and a trend toward shorter OS 
(P = 0.159) in patients with high PRAME expression. The 5-year PFS rate differed significantly between 
patients with high versus low PRAME expression (48.1% versus 61.1%, P = 0.013). Similarly, the 5-year 
OS rate in patients with high PRAME expression was 65.6%, whereas it was 79.1% in patients with low 
PRAME expression (P = 0.130). 
 
3.3 Association of PRAME expression with clinicopathologic features and clinical outcomes 
There were no significant differences between the clinicopathologic features of patients with high and 
low PRAME expression (Table I). We found no significant associations between PRAME expression and 
disease stage, IPI score (low or high), cell of origin (GC subtype or non-GC subtype), CD5 expression, or 
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DHS. The overall response rate (CR and PR) was 89.9% in 138 evaluable DLBCL patients. The CR rate 
was 73.7% for patients with high PRAME expression and 84.0% for patients with low PRAME 
expression (P = 0.269). The PD rate was higher in patients with high PRAME expression (21.1%) than in 
those with low PRAME expression (8.4%), but statistical significance was not reached (P = 0.090). 
Table II shows the results of univariate analysis. In DLBCL patients, older age, poor PS, elevated LDH, 
high IPI score (3-5), and high PRAME expression were significant risk factors for PFS, while older age, 
poor PS, elevated LDH, number of extranodal sites (≥2), advanced disease stage, and high IPI score (3-5) 
were significant risk factors for OS.  
Table III shows the results of multivariate analysis. Multivariate analysis found an interaction between B 
symptoms and PS in prognostic factors; therefore, we identified 4 variants (B symptoms [-] PS 1–2, B 
symptoms [-] PS 2–4, B symptoms [+] PS 1–2, and B symptoms [+] PS 2–4) for the Cox proportional 
hazard model. Thus, elevated LDH, high PRAME expression, as well as combined variate of B symptoms 
(-) PS 2–4, were found to be independent predictors of shorter PFS, while elevated LDH and combined 
variate of B symptoms (-) PS 2–4 were independent predictors of shorter OS. 
3.4 Correlation between qRT-PCR and IHC 
PRAME expression as measured by qRT-PCR was performed on 40 samples of the enrolled patients. 
According to our IHC results, 11 of these patients had high and 29 had low PRAME expression (Fig. 3). 
After examining the correlation, we found that PRAME mRNA expression was significantly higher in 
patients with high PRAME expression than that in patients with low PRAME expression (P = 0.008). 
 
4. Discussion 
In this study, we confirmed that immunohistochemical analysis is a useful technique for the detection 
and assessment of PRAME expression in DLBCL. Univariate and multivariate analysis showed that high 
PRAME expression was significantly associated with shorter PFS in DLBCL patients treated with R-
CHOP therapy, suggesting that high PRAME expression, based on IHC, is a useful marker for predicting 
 
 
10 
poor prognosis in DLBCL patients treated with rituximab-containing chemotherapy. On the other hand, 
IPI score, which is often used in prognostic models to predict the outcome of patients with DLBCL, did 
not predict shorter PFS or shorter OS in our multivariate analysis. The relatively small number of cases 
enrolled in the present study could have affected this result. 
In addition, we found a positive correlation between PRAME expression as classified by IHC and 
PRAME expression as measured by qRT-PCR.  
In various malignancies, an association between high PRAME expression and a poor prognosis and 
advanced stage disease has previously been reported. For instance, high PRAME expression was found in 
advanced stage of neuroblastoma, and it was found to be associated with shorter event-free survival in 
that study [5]. High PRAME expression was an independent marker of short metastasis-free intervals in 
patients with breast cancer [3] and was found to be associated with poor overall survival and lung 
metastases in patients with osteosarcoma [4]. 
In hematologic malignancies, the clinical significance of PRAME expression is controversial. Tanaka et 
al. found PRAME expression in acute leukemia to be higher during relapse than at the time of diagnosis 
[9], and in chronic myeloid leukemia, PRAME expression was shown to increase with disease 
progression from the chronic to the advanced phase [10,11]. On the other hand, high PRAME expression 
was shown to be correlated with a good prognosis in acute myeloid leukemia (AML) in both adult [32] 
and pediatric patients [12], as well as in childhood lymphoblastic leukemia [13]. 
Kawano et al. showed, by means of cDNA microarray analysis, that the expression of the PRAME gene 
is markedly increased in DLBCL patients resistant to anthracycline-containing chemotherapy [25]. They 
also found that DLBCL patients with PRAME expression, as detected by RT-PCR, had a shorter PFS and 
lower response to anthracycline-containing chemotherapy than DLBCL patients without PRAME 
expression. Similarly, we found that there was an association between high PRAME expression and poor 
PFS and a trend toward low chemotherapeutic responses in DLBCL patients treated with R-CHOP 
therapy, which is currently the standard treatment for DLBCL. We did not find a statistically significant 
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difference in the OS and response rates of patients with high or low PRAME expression, but our results 
might have been affected by our methodology (the use of IHC rather than RT-PCR) or the relatively small 
number of cases enrolled in our study. 
Although the function of PRAME has not yet been fully elucidated, it is known that PRAME has 
putative nuclear receptor (NR) boxes, which suggests that it serves as a transcription regulator of nuclear 
receptor signaling. Epping et al. illustrated that in the presence of RA, PRAME interacts with the RA 
receptor (RAR) via NR boxes, and this, in turn, prevents ligand-induced receptor activation and target 
gene transcription [14]. PRAME inhibits RA-induced cell differentiation, growth arrest, and apoptosis, as 
it acts as a dominant repressor of RAR. In addition, PRAME knockdown was shown to decrease the 
proliferation of melanoma cells as well as other solid cancer cells [4,14]. PRAME overexpression also has 
clinical implications in leukemia. We previously reported that PRAME knockdown caused a decrease in 
the colony formation and growth rate, as well as G0/G1-phase cell cycle arrest in K562 cells, which are 
known to highly express PRAME. This suggests that PRAME expression has a role in the progression of 
acute leukemia [9]. Furthermore, Bullinger et al. found that PRAME impaired differentiation and 
increased proliferation of leukemia cells because it inhibited RAR signaling in AML without RAR 
rearrangement [33]. Kewitz et al. also examined the effect of PRAME knockdown on Hodgkin lymphoma 
cell lines. Interestingly, in their studies, Kewitz et al. found that PRAME knockdown resulted in the 
restoration of RAR signaling, but increased the sensitivity of Hodgkin lymphoma cells to cytotoxic agents 
[15]. 
 Taken together, although the clinical implications of PRAME overexpression in DLBCL cells have not 
yet been clarified, our findings suggest that lymphoma cells with high PRAME expression acquire growth 
and survival advantages and resistance to chemotherapeutic agents, which result in low chemotherapeutic 
response and poor survival rates. Moreover, our results suggest that R-CHOP therapy is not an adequate 
therapeutic regimen for DLBCL patients with high PRAME expression, and adding a molecular target for 
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PRAME to the conventional chemotherapeutic regimen may improve the clinical outcomes of these 
patients. 
In conclusion, to our knowledge, the present study is the first to show the prognostic significance of 
PRAME expression in DLBCL patients treated with R-CHOP therapy. PRAME expression based on IHC 
is a novel maker of a poor prognosis in DLBCL patients treated with rituximab-containing standard 
chemotherapy. Further studies, including large prospective studies, are necessary to confirm the 
prognostic significance of PRAME expression, and to clarify the mechanism that leads to the poor 
prognosis in DLBCL patients with high PRAME expression. 
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Figure legends 
Fig. 1: Immunohistochemical staining for PRAME in diffuse large B-cell lymphoma (×400).  
 
The tumor cells contain cytoplasmic granules with various levels of stainability. Scoring of PRAME 
expression was classified into 4 categories based on the percentage of PRAME-positive tumor cells. A, 
scored as 0 (less than 25%); B, scored as 1+ (25% or more but less than 50%); C, scored as 2+ (50% or 
more but less than 75%); D, scored as 3+ (75% or more) and high magnification (insert) shows the 
PRAME-positive tumor cells with cytoplasmic granules (arrow heads) and PRAME-negative tumor cells 
without cytoplasmic granules (arrow). 
 
Fig. 2: Progression-free survival (A) and overall survival (B) according to PRAME expression based on 
immunohistochemistry. 
 
The patients with high PRAME expression (grey) showed significantly poorer progression-free survival 
(PFS) than the patients with low PRAME expression (black) (P = 0.013). The patients with high PRAME 
expression (grey) also tended to have a shorter overall survival (OS) than the patients with low PRAME 
expression (black), but this was not statistically significant (P = 0.159).  
 
Fig. 3: The relative expression of PRAME mRNA in patients with low and high PRAME expression 
classified by immunohistochemistry. 
 
PRAME mRNA expression was significantly higher in patients with high PRAME expression than that in 
those with low PRAME expression (P = 0.008). The top and bottom of each diamond represent the 95% 
confidence interval for each group. The mean line across the middle of each diamond represents the group 
mean. Overlap marks appear as lines above and below the group mean. 
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No.
low
( <75% )
high
( ≥75% )
P
All patients 139 21
Age at diagnosis Median 66 66 67 0.737
Range 17-87 17-87 34-83
Gender Female 74 67 7 0.203
Male 86 72 14
IPI factors
　　Age <61 55 50 5 0.274
≥61 105 89 16
　　Performance status 0–1 134 115 19 0.370
2–4 26 24 2
　　LDH Normal 52 46 6 0.680
Elevated 108 93 15
　　Number of extranodal sites 0–1 121 107 14 0.305
≥2 39 32 7
　　Stage I–II 75 64 11 0.588
III–IV 85 75 10
IPI score Low (0-2) 93 81 12 0.922
High (3-5) 67 58 9
B symptom (-) 127 111 16 0.699
(+) 33 28 5
Bulky disease (-) 146 127 19 0.893
(+) 14 12 2
Cell of origin GC 54 46 8 0.651
Non-GC 106 93 13
CD5 Negative 154 133 21 0.332
Positive 6 6 0
Double-hit score 0-1 148 127 21 0.162
2 12 12 0
Chemotherapy response
　　Complete response (CR) 114 100 14 0.334
　　Partial response (PR) 10 9 1
　　Progressive disease (PD) 14 10 4
　　Not available 22 20 2
Table 1. Patient characteristics according to PRAME expression based on IHC
PRAME expression
IHC: immunohistochemistry, IPI: international prognositic index, LDH: lactate dehydrogenase,
GC: germinal center-type, 
Characteristics
HR 95%CI P HR 95%CI P
Gender, Male vs Female 1.11 0.63-1.98 0.719 1.63 0.80-3.51 0.181
Age, ≥61 vs <61 2.10 1.11-4.33 0.022 2.85 1.25-7.71 0.012
Performance status, 2-4 vs 0–1 2.29 1.07-4.47 0.034 3.89 1.66-8.53 0.003
LDH, Elevated vs Normal 8.90 3.59-29.6 <0.001 6.48 2.29-27.1 <0.001
Number of extranodal sites, ≥2 vs 0–1 1.09 0.53-2.06 0.805 2.17 1.00-4.45 0.049
Stage, III–IV vs I–II 1.76 0.99-3.22 0.053 2.93 1.37-6.99 0.005
IPI score, High(3-5) vs Low (0-2) 2.12 1.21-3.76 0.009 4.40 2.12-9.80 <0.001
B symptom, (+) vs (-) 1.00 0.68-2.65 0.349 1.56 0.65-3.36 0.299
Bulky disease, (+) vs (-) 1.44 0.50-3.31 0.462 1.16 0.28-3.28 0.813
Cell of origin, nonGC vs GC 1.27 0.68-2.49 0.456 1.00 0.48-2.22 0.994
CD5, (+) vs (-) 1.22 0.20-3.93 0.793 2.43 0.39-8.14 0.284
DHS, 2 vs 0-1 1.14 0.34-2.81 0.806 2.12 0.63-5.47 0.202
PRAME, high vs low 2.40 1.12-4.67 0.026 1.89 0.70-4.34 0.194
Values of P < 0.05 were considered statistically significant. 
HR: hazard ratio, CI: confidence interval, LDH: lactate dehydrogenase, IPI: international prognositic index
Table 2. Univariate analysis in terms of PFS and OS in DLBCL patients treated with R-CHOP
therapy
PFS OS
R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone
PFS: progression free survival, OS: overall survival, DLBCL: diffuse large B-cell lymphoma
GC: germinal center-type, DHS: double-hit score
PFS HR 95%CI P
　LDH, Elevated vs Normal 8.89 3.26-31.3 <0.001
　B symptom (-), PS 2–4 vs B symptom (-) PS 0–1 6.89 2.17-20.1 0.004
　PRAME, high vs low 3.73 1.65-7.93 0.002
OS
　LDH, Elevated vs Normal 4.30 1.26-20.2 0.019
　B symptom (-), PS 2–4 vs B symptom (-) PS 0–1 4.58 1.30-14.7 0.020
Values of P < 0.05 were considered statistically significant. 
HR: hazard ratio, CI: confidence interval, LDH: lactate dehydrogenase, PS: performance status 
R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone
PFS: progression free survival, OS: overall survival, DLBCL: diffuse large B-cell lymphoma
Table 3. Multivariate analysis in terms of PFS and OS in DLBCL patients treated
with R-CHOP
